CSB and SMARCAL1 compete for RPA32 at stalled forks and differentially control the fate of stalled forks in BRCA2-deficient cells

• Published in: Nucleic acids research Vol. 52; no. 9; pp. 5067 - 5087
• Main Authors: Batenburg, Nicole L, Sowa, Dana J, Walker, John R, Andres, Sara N, Zhu, Xu-Dong
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 22.05.2024
• Subjects: BRCA2 Protein - genetics; BRCA2 Protein - metabolism; Cell Line, Tumor; DNA Helicases - genetics; DNA Helicases - metabolism; DNA Repair; DNA Repair Enzymes - genetics; DNA Repair Enzymes - metabolism; DNA Replication; Genome Integrity, Repair and; Humans; Poly-ADP-Ribose Binding Proteins - genetics; Poly-ADP-Ribose Binding Proteins - metabolism; Protein Binding; Replication Protein A - genetics; Replication Protein A - metabolism
• ISSN: 0305-1048; 1362-4962
• DOI: 10.1093/nar/gkae154

CSB (Cockayne syndrome group B) and SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent, regulator of chromatin, subfamily A-like 1) are DNA translocases that belong to the SNF2 helicase family. They both are enriched at stalled replication forks. While SMARCAL1 is recruited by RPA32 to stalled forks, little is known about whether RPA32 also regulates CSB's association with stalled forks. Here, we report that CSB directly interacts with RPA, at least in part via a RPA32C-interacting motif within the N-terminal region of CSB. Modeling of the CSB-RPA32C interaction suggests that CSB binds the RPA32C surface previously shown to be important for binding of UNG2 and SMARCAL1. We show that this interaction is necessary for promoting fork slowing and fork degradation in BRCA2-deficient cells but dispensable for mediating restart of stalled forks. CSB competes with SMARCAL1 for RPA32 at stalled forks and acts non-redundantly with SMARCAL1 to restrain fork progression in response to mild replication stress. In contrast to CSB stimulated restart of stalled forks, SMARCAL1 inhibits restart of stalled forks in BRCA2-deficient cells, likely by suppressing BIR-mediated repair of collapsed forks. Loss of CSB leads to re-sensitization of SMARCAL1-depleted BRCA2-deficient cells to chemodrugs, underscoring a role of CSB in targeted cancer therapy.